{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:52:25Z","timestamp":1778903545861,"version":"3.51.4"},"reference-count":126,"publisher":"Oxford University Press (OUP)","issue":"Supplement_6","license":[{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,24]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The treatment options for PsA have substantially expanded over the last decade. Approximately 40% of patients will not respond to first-line anti-TNF-\u03b1 therapies. There is limited data to help clinicians select the most appropriate biologic therapy for PsA patients, including guidance for decisions on biologic therapy switching. In this review we will examine the current understanding of predictors of response to treatment. Imaging technology has evolved to allow us to better study psoriatic disease and define disease activity, including synovitis and enthesitis. Enthesitis is implicated in the pathogenesis, diagnosis and prognosis of PsA. It appears to be a common thread among all of the various PsA clinical presentations. Enthesitis mainly manifests as tenderness, which is difficult to distinguish from FM, chronic pain and mechanically associated enthesopathy, and it might be relevant for understanding the apparent 40% failure of existing therapy. Excess adipose tissue makes if more difficult to detect joint swelling clinically, as many PsA patients have very high BMIs. Integrating imaging and clinical assessment with biomarker analysis could help to deliver stratified medicine in PsA and allow better treatment decision making. This could include which patients require ongoing biologic therapy, which class of biologic therapy that should be, and who alternatively requires management of non-inflammatory disease.<\/jats:p>","DOI":"10.1093\/rheumatology\/keab504","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T19:11:42Z","timestamp":1624475502000},"page":"vi38-vi52","source":"Crossref","is-referenced-by-count":12,"title":["Integrating imaging and biomarker assessment to better define psoriatic arthritis and predict response to biologic therapy"],"prefix":"10.1093","volume":"60","author":[{"given":"Ashley","family":"Elliott","sequence":"first","affiliation":[{"name":"Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"},{"name":"Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeleine","family":"Rooney","sequence":"additional","affiliation":[{"name":"Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,12,24]]},"reference":[{"key":"2021122420120496200_keab504-B1","first-page":"ii14","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64(Suppl 2","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B2","first-page":"1251","article-title":"New GRAPPA and EULAR recommendations for the management of psoriatic arthritis","volume":"56","author":"Coates","year":"2017","journal-title":"Rheumatology"},{"key":"2021122420120496200_keab504-B3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-2474-14-101","article-title":"The TICOPA protocol (tight control of psoriatic arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis","volume":"14","author":"Coates","year":"2013","journal-title":"BMC Musculoskelet Disord"},{"key":"2021122420120496200_keab504-B4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/rheumatology\/keu328","article-title":"Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era","volume":"54","author":"McGonagle","year":"2015","journal-title":"Rheumatology"},{"key":"2021122420120496200_keab504-B5","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/rheumatology\/kez505","article-title":"Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis","volume":"59","author":"Iannone","year":"2020","journal-title":"Rheumatology"},{"key":"2021122420120496200_keab504-B6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12016-017-8630-7","article-title":"Clinical features of psoriatic arthritis: a comprehensive review of unmet clinical needs","volume":"55","author":"McArdle","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"2021122420120496200_keab504-B7","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1136\/annrheumdis-2019-215321","article-title":"Swollen, but not tender joints, are independently associated with ultrasound synovitis: results from a longitudinal observational study of patients with established rheumatoid arthritis","volume":"78","author":"Hammer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13075-018-1802-x","article-title":"Significant association between joint ultrasonographic parameters and synovial inflammatory factors in rheumatoid arthritis","volume":"21","author":"Kondo","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2021122420120496200_keab504-B9","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/acr.20155","article-title":"Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data","volume":"62","author":"Coates","year":"2010","journal-title":"Arthritis Care Res"},{"key":"2021122420120496200_keab504-B10","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","article-title":"The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)","volume":"72","author":"Helliwell","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B11","first-page":"S48","article-title":"Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for PSoriatic Arthritis (DAPSA). A brief review","volume":"33","author":"Smolen","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2021122420120496200_keab504-B12","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard.2008.094946","article-title":"Treatment recommendations for psoriatic arthritis","volume":"68","author":"Ritchlin","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B13","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keab246.012","article-title":"O13 Which composite measure best reflects disease activity and predicts treatment change in psoriatic arthritis?","author":"Tucker","year":"2021","journal-title":"Rheumatology"},{"key":"2021122420120496200_keab504-B14","first-page":"65","article-title":"Psoriatic arthritis: state of the art review","volume":"17","author":"Coates","year":"2017","journal-title":"Clin Med J R Coll Physicians London"},{"key":"2021122420120496200_keab504-B15","first-page":"1021","article-title":"Clinical characteristics and disease activity in psoriatic arthritis patients with dactylitis or enthesitis: results from Corrona registry","volume":"40","author":"Mease","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2021122420120496200_keab504-B16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13075-017-1399-5","article-title":"The association between sonographic enthesitis and radiographic damage in psoriatic arthritis","volume":"19","author":"Polachek","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2021122420120496200_keab504-B17","first-page":"350","article-title":"The relationship between vitamin D, vertebral deformity and quality of life in psoriatic arthritis","volume":"41","author":"Baskan","year":"2016","journal-title":"Acta Reumatol Port"},{"key":"2021122420120496200_keab504-B18","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/annrheumdis-2013-203643","article-title":"Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells","volume":"73","author":"Jacques","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B19","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/rheumatology\/kex179","article-title":"Musculoskeletal ultrasonography for psoriatic arthritis and psoriasis patients: a systematic literature review","volume":"56","author":"Zabotti","year":"2017","journal-title":"Rheumatology"},{"key":"2021122420120496200_keab504-B20","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3899\/jrheum.171411","article-title":"Ultrasonographic and clinical assessment of peripheral enthesitis in patients with psoriatic arthritis, psoriasis, and fibromyalgia syndrome: the ULISSE study","volume":"46","author":"Macchioni","year":"2019","journal-title":"J Rheumatol"},{"key":"2021122420120496200_keab504-B21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.semarthrit.2013.04.005","article-title":"Enthesitis in psoriatic arthritis","volume":"43","author":"Sakkas","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"2021122420120496200_keab504-B22","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1002\/acr.20577","article-title":"Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander\/Newcastle Enthesitis Index (MEI), Leeds","volume":"63(Suppl 11","author":"Mease","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2021122420120496200_keab504-B23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.semarthrit.2018.02.002","article-title":"Enthesitis: a hallmark of psoriatic arthritis","volume":"48","author":"Kaeley","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2021122420120496200_keab504-B24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2021122420120496200_keab504-B25","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B26","doi-asserted-by":"crossref","first-page":"e000017","DOI":"10.1136\/rmdopen-2014-000017","article-title":"Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis","volume":"1","author":"Maneiro","year":"2015","journal-title":"RMD Open"},{"key":"2021122420120496200_keab504-B27","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/annrheumdis-2013-204448","article-title":"Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis","volume":"74","author":"Eder","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B28","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/annrheumdis-2012-201972","article-title":"Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA)","volume":"73","author":"Theander","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B29","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar3021","article-title":"Remission in psoriatic arthritis: is it possible and how can it be predicted?","volume":"12","author":"Saber","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2021122420120496200_keab504-B30","doi-asserted-by":"crossref","first-page":"e000415","DOI":"10.1136\/rmdopen-2016-000415","article-title":"Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial","volume":"3","author":"Mease","year":"2017","journal-title":"RMD Open"},{"key":"2021122420120496200_keab504-B31","doi-asserted-by":"crossref","first-page":"862969","DOI":"10.1155\/2014\/862969","article-title":"Drug retention rates and treatment discontinuation among anti-TNF-\u03b1 agents in psoriatic arthritis and ankylosing spondylitis in clinical practice","volume":"2014","author":"Fabbroni","year":"2014","journal-title":"Mediators Inflamm"},{"key":"2021122420120496200_keab504-B32","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3109\/03009742.2014.962081","article-title":"Two-year survival rates of anti-TNF-\u03b1 therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA","volume":"44","author":"Iannone","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"2021122420120496200_keab504-B33","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12325-012-0037-5","article-title":"Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings","volume":"29","author":"Bonafede","year":"2012","journal-title":"Adv Ther"},{"key":"2021122420120496200_keab504-B34","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.30117","article-title":"Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor \u03b1 therapy: results from the nationwide Danish DANBIO registry","volume":"63","author":"Glintborg","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2021122420120496200_keab504-B35","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40268-017-0215-7","article-title":"Switching between biological treatments in psoriatic arthritis: a review of the evidence","volume":"17","author":"Costa","year":"2017","journal-title":"Drugs R D"},{"key":"2021122420120496200_keab504-B36","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"2021122420120496200_keab504-B37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B38","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet (London)"},{"key":"2021122420120496200_keab504-B39"},{"key":"2021122420120496200_keab504-B40"},{"key":"2021122420120496200_keab504-B41"},{"key":"2021122420120496200_keab504-B42","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2021122420120496200_keab504-B43"},{"key":"2021122420120496200_keab504-B44"},{"key":"2021122420120496200_keab504-B45"},{"key":"2021122420120496200_keab504-B46"},{"key":"2021122420120496200_keab504-B47","first-page":"142","article-title":"OP0217 Ustekinumab is superior to TNF inhibitor treatment in resolving enthesitis in PSA patients with active enthesitis\u2014results from the Enthesial CLearance In PSoriatic Arthritis (ECLIPSA) study","volume":"76","author":"Araujo","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.15557\/JoU.2016.0007","article-title":"Diagnostic imaging of psoriatic arthritis. Part I: etiopathogenesis, classifications and radiographic features","volume":"16","author":"Sudo\u0142-Szopi\u0144ska","year":"2016","journal-title":"J Ultrason"},{"key":"2021122420120496200_keab504-B49","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/annrheumdis-2016-209853","article-title":"Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis","volume":"76","author":"Jadon","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B50","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/1529-0131(200003)43:3<576::AID-ANR14>3.0.CO;2-A","article-title":"The mechanism of formation of bony spurs (enthesophytes) in the Achilles tendon","volume":"43","author":"Benjamin","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2021122420120496200_keab504-B51","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/03009740600906677","article-title":"Dactylitis, a term for different digit diseases","volume":"35","author":"Olivieri","year":"2006","journal-title":"Scand J Rheumatol"},{"key":"2021122420120496200_keab504-B52","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.3899\/jrheum.141010","article-title":"Validation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) for the hand and foot in a randomized placebo-controlled trial","volume":"42","author":"Glinatsi","year":"2015","journal-title":"J Rheumatol"},{"key":"2021122420120496200_keab504-B53","first-page":"1953","article-title":"Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study","volume":"26","author":"Oostveen","year":"1999","journal-title":"J Rheumatol"},{"key":"2021122420120496200_keab504-B54","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/ard.2008.100149","article-title":"Effect of adalimumab on joint disease: features of patients with psoriatic arthritis detected by magnetic resonance imaging","volume":"69","author":"Anandarajah","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B55","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/ard.2007.076091","article-title":"The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis","volume":"67","author":"Anandarajah","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B56","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/ard.2006.063818","article-title":"Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis","volume":"66","author":"Marzo-Ortega","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B57","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13075-018-1653-5","article-title":"Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study","volume":"20","author":"Kampylafka","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2021122420120496200_keab504-B58","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/ard.2010.139667","article-title":"Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B59","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3899\/jrheum.170408","article-title":"Whole-body magnetic resonance imaging in axial spondyloarthritis: reduction of sacroiliac, spinal, and entheseal inflammation in a placebo-controlled trial of adalimumab","volume":"45","author":"Krabbe","year":"2018","journal-title":"J Rheumatol"},{"key":"2021122420120496200_keab504-B60","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3899\/jrheum.181093","article-title":"The OMERACT MRI in enthesitis initiative: definitions of key pathologies, suggested MRI sequences, and a novel heel enthesitis scoring system","volume":"46","author":"Mathew","year":"2019","journal-title":"J Rheumatol"},{"key":"2021122420120496200_keab504-B61","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/acr.22191","article-title":"Defining enthesitis in spondyloarthritis by ultrasound: results of a Delphi process and of a reliability reading exercise","volume":"66","author":"Terslev","year":"2014","journal-title":"Arthritis Care Res"},{"key":"2021122420120496200_keab504-B62","first-page":"1639","article-title":"Atlas of the OMERACT Heel Enthesitis MRI Scoring System (HEMRIS)","volume":"24","author":"Schmoldt","year":"1975","journal-title":"RMD Open"},{"key":"2021122420120496200_keab504-B63","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/ard.2007.084251","article-title":"Validity of enthesis ultrasound assessment in spondyloarthropathy","volume":"68","author":"De Miguel","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B64","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.61.10.905","article-title":"Ultrasonography of entheseal insertions in the lower limb in spondyloarthropathy","volume":"61","author":"Balint","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B65","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1136\/annrheumdis-2018-213609","article-title":"Reliability of a consensus-based ultrasound definition and scoring for enthesitis in spondyloarthritis and psoriatic arthritis: an OMERACT US initiative","volume":"77","author":"Balint","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B66","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3899\/jrheum.171465","article-title":"Development of a preliminary ultrasonographic enthesitis score in psoriatic arthritis\u2014GRAPPA ultrasound working group","volume":"46","author":"Tom","year":"2019","journal-title":"J Rheumatol"},{"key":"2021122420120496200_keab504-B67","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1186\/s13075-014-0476-2","article-title":"Ultrasound composite scores for the assessment of inflammatory and structural pathologies in Psoriatic Arthritis (PsASon-Score)","volume":"16","author":"Ficjan","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2021122420120496200_keab504-B68","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/art.24646","article-title":"Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice: a pilot project","volume":"61","author":"Backhaus","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2021122420120496200_keab504-B69","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1186\/1471-2474-14-358","article-title":"Evaluation of the novel ultrasound score for large joints in psoriatic arthritis and ankylosing spondylitis: six month experience in daily clinical practice","volume":"14","author":"Sch\u00e4fer","year":"2013","journal-title":"BMC Musculoskelet Disord"},{"key":"2021122420120496200_keab504-B70","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.berh.2016.08.012","article-title":"Imaging in the diagnosis and management of peripheral psoriatic arthritis\u2014the clinical utility of magnetic resonance imaging and ultrasonography","volume":"30","author":"\u00d8stergaard","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2021122420120496200_keab504-B71","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2019-215589","article-title":"MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group","volume":"78","author":"Maksymowych","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B72","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.21445","article-title":"Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis","volume":"53","author":"Maksymowych","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2021122420120496200_keab504-B73","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1136\/annrheumdis-2012-201545","article-title":"Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRI","volume":"72","author":"Althoff","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B74","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/art.39458","article-title":"Enthesitis: new insights into pathogenesis, diagnostic modalities, and treatment","volume":"68","author":"Kehl","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021122420120496200_keab504-B75","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1136\/annrheumdis-2016-210424","article-title":"Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?","volume":"76","author":"Alivernini","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B76","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1093\/rheumatology\/kez237","article-title":"Evaluating current definitions of low disease activity in psoriatic arthritis using ultrasound","volume":"58","author":"Bosch","year":"2019","journal-title":"Rheumatology"},{"key":"2021122420120496200_keab504-B77","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fmed.2020.00487","article-title":"Ultrasound imaging in psoriatic arthritis: what have we learnt in the last five years?","volume":"7","author":"Dubash","year":"2020","journal-title":"Front Med"},{"key":"2021122420120496200_keab504-B78","first-page":"31","article-title":"Assessment of enthesis in patients with psoriatic arthritis and fibromyalgia using clinical examination and ultrasound","volume":"38(Suppl 123","author":"Fiorenza","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2021122420120496200_keab504-B79","first-page":"abstract no. 2472","article-title":"The role of ultrasound for the assessment of psoriatic arthritis patients with fibromyalgia\u2014interim analysis [abstract]","volume":"71(Suppl 10","author":"Polachek","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2021122420120496200_keab504-B80","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1007\/s10067-019-04674-3","article-title":"Musculoskeletal ultrasound in monitoring response to apremilast in psoriatic arthritis patients: results from a longitudinal study","volume":"38","author":"Ceccarelli","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2021122420120496200_keab504-B81","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/acr.23693","article-title":"Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: a prospective cohort study","volume":"71","author":"H\u00f8jgaard","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2021122420120496200_keab504-B82","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jbspin.2015.01.016","article-title":"Ultrasound study of entheses in psoriasis patients with or without musculoskeletal symptoms: a prospective study","volume":"82","author":"Acquacalda","year":"2015","journal-title":"Joint Bone Spine"},{"key":"2021122420120496200_keab504-B83","first-page":"733","article-title":"Persistence of enthesopathic changes in patients with spondylarthropathy during a 6-month follow-up","volume":"13","author":"Lehtinen","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"2021122420120496200_keab504-B84","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s10067-006-0460-6","article-title":"The effects of sulfasalazine treatment on enthesal abnormalities of inflammatory rheumatic diseases","volume":"26","author":"Genc","year":"2007","journal-title":"Clin Rheumatol"},{"key":"2021122420120496200_keab504-B85","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10067-014-2673-4","article-title":"Responsiveness to therapy change of a global ultrasound assessment in spondyloarthritis patients","volume":"34","author":"Ruta","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2021122420120496200_keab504-B86","first-page":"844","article-title":"Colour Doppler ultrasonography can be used to detect the changes of sacroiliitis and peripheral enthesitis in patients with ankylosing spondylitis during adalimumab treatment","volume":"33","author":"Hu","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2021122420120496200_keab504-B87","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/acr.22195","article-title":"Value of contrast-enhanced ultrasonography for the detection and quantification of enthesitis vascularization in patients with spondyloarthritis","volume":"66","author":"Mouterde","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021122420120496200_keab504-B88","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s10067-015-2880-7","article-title":"Comparison between full and tapered dosages of biologic therapies in psoriatic arthritis patients: clinical and ultrasound assessment","volume":"34","author":"Janta","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2021122420120496200_keab504-B89","first-page":"161","article-title":"Clinical assessment and ultrasonography in the follow-up of enthesitis in patients with spondyloarthritis: a multicenter ultrasound study in daily clinical practice","volume":"10","author":"Hartung","year":"2018","journal-title":"Open Access Rheumatol Res Rev"},{"key":"2021122420120496200_keab504-B90","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.3899\/jrheum.100136","article-title":"Power Doppler ultrasonography assessment of entheses in spondyloarthropathies: response to therapy of entheseal abnormalities","volume":"37","author":"Naredo","year":"2010","journal-title":"J Rheumatol"},{"key":"2021122420120496200_keab504-B91","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/art.40778","article-title":"Regression of peripheral subclinical enthesopathy in therapy-na\u00efve patients treated with Ustekinumab for moderate-to-severe chronic plaque psoriasis","volume":"71","author":"Savage","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2021122420120496200_keab504-B92","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/rheumatology\/kes014","article-title":"Development of a preliminary US power Doppler composite score for monitoring treatment in PsA","volume":"51","author":"Gutierrez","year":"2012","journal-title":"Rheumatology"},{"key":"2021122420120496200_keab504-B93","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.semarthrit.2017.05.002","article-title":"Ultrasound entheseal abnormalities at the distal interphalangeal joints and clinical nail involvement in patients with psoriasis and psoriatic arthritis, supporting the nail-enthesitis theory","volume":"47","author":"Acosta-Felquer","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2021122420120496200_keab504-B94","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000343607","article-title":"Ultrasonographic assessment of nail in psoriatic disease shows a link between onychopathy and distal interphalangeal joint extensor tendon enthesopathy","volume":"225","author":"Aydin","year":"2012","journal-title":"Dermatology"},{"key":"2021122420120496200_keab504-B95","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/annrheumdis-2011-200478","article-title":"Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails","volume":"71","author":"Ash","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B96","doi-asserted-by":"crossref","first-page":"e021942","DOI":"10.1136\/bmjopen-2018-021942","article-title":"Clinical and ultrasonographic predictors for achieving minimal disease activity in patients with psoriatic arthritis: the UPSTREAM (Ultrasound in PSoriatic arthritis TREAtMent) prospective observational study protocol","volume":"8","author":"Canzoni","year":"2018","journal-title":"BMJ Open"},{"key":"2021122420120496200_keab504-B97","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Atkinson","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"2021122420120496200_keab504-B98","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/jid.2011.376","article-title":"TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis","volume":"132","author":"Tejasvi","year":"2012","journal-title":"J Invest Dermatol"},{"key":"2021122420120496200_keab504-B99","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.4161\/cc.26699","article-title":"IL-17 signaling and A20, a balancing act","volume":"12","author":"Garg","year":"2013","journal-title":"Cell Cycle"},{"key":"2021122420120496200_keab504-B100","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/rheumatology\/kel175","article-title":"The -308 tumour necrosis factor-\u03b1 gene polymorphism predicts therapeutic response to TNF\u03b1-blockers in rheumatoid arthritis and spondyloarthritis patients","volume":"46","author":"Seitz","year":"2007","journal-title":"Rheumatology"},{"key":"2021122420120496200_keab504-B101","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1038\/jid.2014.123","article-title":"TNF-\u03b1 gene polymorphisms: association with disease susceptibility and response to anti-TNF-\u03b1 treatment in psoriatic arthritis","volume":"134","author":"Murdaca","year":"2014","journal-title":"J Invest Dermatol"},{"key":"2021122420120496200_keab504-B102","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jbspin.2012.02.003","article-title":"Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis","volume":"79","author":"Morales-Lara","year":"2012","journal-title":"Joint Bone Spine"},{"key":"2021122420120496200_keab504-B103","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3899\/jrheum.110980","article-title":"FCGR2A\/CD32A and FCGR3A\/CD16A variants and EULAR response to tumor necrosis factor-\u03b1 blockers in psoriatic arthritis: a longitudinal study with 6 months of followup","volume":"39","author":"Ram\u00edrez","year":"2012","journal-title":"J Rheumatol"},{"key":"2021122420120496200_keab504-B104","doi-asserted-by":"crossref","first-page":"e17160","DOI":"10.1371\/journal.pone.0017160","article-title":"The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans","volume":"6","author":"Di Meglio","year":"2011","journal-title":"PLoS One"},{"key":"2021122420120496200_keab504-B105","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/tpj.2016.70","article-title":"IL17RA gene variants and anti-TNF response among psoriasis patients","volume":"18","author":"Batalla","year":"2018","journal-title":"Pharmacogenomics J"},{"key":"2021122420120496200_keab504-B106","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/prca.201500046","article-title":"Developing clinically relevant biomarkers in inflammatory arthritis: a multiplatform approach for serum candidate protein discovery","volume":"10","author":"Mcardle","year":"2016","journal-title":"Proteomics Clin Appl"},{"key":"2021122420120496200_keab504-B107","doi-asserted-by":"crossref","first-page":"e15004","DOI":"10.1371\/journal.pone.0015004","article-title":"Aptamer-based multiplexed proteomic technology for biomarker discovery","volume":"5","author":"Gold","year":"2010","journal-title":"PLoS One"},{"key":"2021122420120496200_keab504-B108","doi-asserted-by":"crossref","first-page":"e12556","DOI":"10.1371\/journal.pone.0012556","article-title":"Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placebo","volume":"5","author":"Tak","year":"2010","journal-title":"PLoS One"},{"key":"2021122420120496200_keab504-B109","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3899\/jrheum.121162","article-title":"Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis","volume":"40","author":"Chandran","year":"2013","journal-title":"J Rheumatol"},{"key":"2021122420120496200_keab504-B110","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2710.2006.00715.x","article-title":"Short-term infliximab therapy improves symptoms of psoriatic arthritis and decreases concentrations of cartilage oligomeric matrix protein","volume":"31","author":"Cauza","year":"2006","journal-title":"J Clin Pharm Ther"},{"key":"2021122420120496200_keab504-B111","first-page":"665","article-title":"Differential expression of proteins with heparin affinity in patients with rheumatoid and psoriatic arthritis: a preliminary study","volume":"31","author":"Grazio","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2021122420120496200_keab504-B112","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1080\/03009742.2019.1577490","article-title":"Hyaluronan concentration and molecular mass in psoriatic arthritis: biomarkers of disease severity, resistance to treatment, and outcome","volume":"48","author":"Hellman","year":"2019","journal-title":"Scand J Rheumatol"},{"key":"2021122420120496200_keab504-B113","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+ CD4\u2013 CD8\u2013 entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"key":"2021122420120496200_keab504-B114","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nrrheum.2012.41","article-title":"Genetics of spondyloarthritis\u2014beyond the MHC","volume":"8","author":"Reveille","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"2021122420120496200_keab504-B115","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/art.38638","article-title":"Interleukin-23 mediates the intestinal response to microbial \u03b2-1,3-glucan and the development of spondyloarthritis pathology in SKG mice","volume":"66","author":"Benham","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2021122420120496200_keab504-B116","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/annrheumdis-2016-209454","article-title":"A20 inhibition of STAT1 expression in myeloid cells: a novel endogenous regulatory mechanism preventing development of enthesitis","volume":"76","author":"De Wilde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B117","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/annrheumdis-2012-201697","article-title":"Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab","volume":"72","author":"Wagner","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B118","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s10067-010-1528-x","article-title":"Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNF\u03b1 inhibitors","volume":"29","author":"Pedersen","year":"2010","journal-title":"Clin Rheumatol"},{"key":"2021122420120496200_keab504-B119","doi-asserted-by":"crossref","first-page":"906349","DOI":"10.1155\/2015\/906349","article-title":"The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1)","volume":"2015","author":"Schafer","year":"2015","journal-title":"J Immunol Res"},{"key":"2021122420120496200_keab504-B120","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/annrheumdis-2014-205417","article-title":"Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis","volume":"75","author":"Ademowo","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2021122420120496200_keab504-B121","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/art.40581","article-title":"Brief report: interleukin-17 blockade with secukinumab in peripheral spondyloarthritis impacts synovial immunopathology without compromising systemic immune responses","volume":"70","author":"Van Mens","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2021122420120496200_keab504-B122","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1186\/ar3188","article-title":"Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study","volume":"12","author":"Visvanathan","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2021122420120496200_keab504-B123","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.7150\/thno.31144","article-title":"In-depth serum proteomics reveals biomarkers of psoriasis severity and response to traditional Chinese medicine","volume":"9","author":"Xu","year":"2019","journal-title":"Theranostics"},{"key":"2021122420120496200_keab504-B124","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11306-019-1527-0","article-title":"Pro- and anti-inflammatory eicosanoids in psoriatic arthritis","volume":"15","author":"Coras","year":"2019","journal-title":"Metabolomics"},{"key":"2021122420120496200_keab504-B125","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/prca.201500051","article-title":"A clinically based protein discovery strategy to identify potential biomarkers of response to anti-TNF-\u03b1 treatment of psoriatic arthritis","volume":"10","author":"Collins","year":"2016","journal-title":"Proteomics Clin Appl"},{"key":"2021122420120496200_keab504-B126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1559-0275-12-1","article-title":"Quantitative tandem mass-spectrometry of skin tissue reveals putative psoriatic arthritis biomarkers","volume":"12","author":"Cretu","year":"2015","journal-title":"Clin Proteomics"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/Supplement_6\/vi38\/41928896\/keab504.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/Supplement_6\/vi38\/41928896\/keab504.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T07:44:58Z","timestamp":1699170298000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/Supplement_6\/vi38\/6482901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":126,"journal-issue":{"issue":"Supplement_6","published-online":{"date-parts":[[2021,12,24]]},"published-print":{"date-parts":[[2021,12,24]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab504","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,11,1]]}}}